A little-known medical device maker could get a big lift as insurers and government programs cover more testing for swelling after cancer treatment and for people with heart failure. The key question is whether hospitals move fast enough and testing demand holds up to turn those coverage wins into steady subscription-like revenue.Read more
ImpediMed sells the SOZO device, which helps clinics spot and manage swelling after breast cancer treatment and support care for heart failure and weight-loss patients. Faster insurance coverage and wider hospital adoption could drive steady demand, but slow hospital buying cycles and the risk of needing more funding could get in the way.Read more
Catalysts About ImpediMed ImpediMed develops and commercializes SOZO, a bioimpedance spectroscopy platform used to monitor fluid status and body composition across lymphedema, heart failure and related conditions. What are the underlying business or industry changes driving this perspective?Read more
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.
